344 related articles for article (PubMed ID: 22168167)
21. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
Cepero V; Sierra JR; Giordano S
Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
[TBL] [Abstract][Full Text] [Related]
23. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
24. BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis.
Seo SI; Gera L; Zhau HE; Qian WP; Iqbal S; Johnson NA; Zhang S; Zayzafoon M; Stewart J; Wang R; Chung LW; Wu D
Clin Cancer Res; 2008 Oct; 14(19):6198-206. PubMed ID: 18829499
[TBL] [Abstract][Full Text] [Related]
25. CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.
Liu P; Liang Y; Jiang L; Wang H; Wang S; Dong J
Int J Oncol; 2018 Oct; 53(4):1544-1556. PubMed ID: 30066854
[TBL] [Abstract][Full Text] [Related]
26. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Rice L; Lepler S; Pampo C; Siemann DW
Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
Tibes R; Trent J; Kurzrock R
Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181
[TBL] [Abstract][Full Text] [Related]
28. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Quatrale AE; Porcelli L; Silvestris N; Colucci G; Angelo A; Azzariti A
Front Biosci (Landmark Ed); 2011 Jan; 16(5):1962-72. PubMed ID: 21196276
[TBL] [Abstract][Full Text] [Related]
29. Protein tyrosine phosphatases as novel targets in breast cancer therapy.
Nunes-Xavier CE; Martín-Pérez J; Elson A; Pulido R
Biochim Biophys Acta; 2013 Dec; 1836(2):211-26. PubMed ID: 23756181
[TBL] [Abstract][Full Text] [Related]
30. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
31. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
[TBL] [Abstract][Full Text] [Related]
32. Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.
Tuttle RM; Brose MS
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):12-3. PubMed ID: 27168343
[No Abstract] [Full Text] [Related]
33. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
[TBL] [Abstract][Full Text] [Related]
34. Natural products as important tyrosine kinase inhibitors.
Yin B; Fang DM; Zhou XL; Gao F
Eur J Med Chem; 2019 Nov; 182():111664. PubMed ID: 31494475
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase inhibitors for the treatment of prostate cancer.
Chau V; Madan RA; Aragon-Ching JB
Expert Opin Pharmacother; 2021 Oct; 22(14):1889-1899. PubMed ID: 33989112
[TBL] [Abstract][Full Text] [Related]
36. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
37. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
Matos I; Elez E; Capdevila J; Tabernero J
Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
[TBL] [Abstract][Full Text] [Related]
38. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate.
George DJ
Urology; 2002 Sep; 60(3 Suppl 1):115-21; discussion 122. PubMed ID: 12231066
[TBL] [Abstract][Full Text] [Related]
39. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
40. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.
Zámečníkova A
Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
